Jasper Therapeutics has appointed Dr. Daniel Adelman as its acting chief medical officer.

Adelman has worked in the realm of immunology for more than 30 years. He has held leadership posts at Genentech (as a clinical scientist) and Pharmacyclics (as VP of clinical operations and biometrics) and served as chief medical officer at Aimmune Therapeutics, Sunesis Pharmaceuticals and Alvine Pharmaceuticals.

“We are delighted to welcome Dan to the Jasper team as acting chief medical officer,” said Jasper Therapeutics CEO Ron Martell in a statement. “Dr. Adelman is an extremely experienced drug developer and leader in the field of immune-based therapeutics and has an impressive track record of success in bringing new drugs to market. His deep knowledge and expertise will be invaluable in advancing our mission of improving patient outcomes through innovative therapies for chronic spontaneous urticaria and other mast cell diseases.”

During his Genentech tenure, Adelman contributed to the development of omalizumab and bevacizumab. He has worked on numerous therapies for celiac disease and food allergy.

“I am thrilled to be working with the team at Jasper Therapeutics at this stage of their development,” Adelman said in the statement. “The data on briquilimab reported to date are compelling, and I believe the company is well positioned to bring promising novel treatments to patients with unmet needs in mast and stem cell diseases such as chronic spontaneous urticaria and low- to intermediate-risk MDS, as well as to patients undergoing stem cell transplants.”

Adelman’s career started at the University of California, San Francisco School of Medicine’s Division of Allergy and Immunology, where he was an assistant professor of clinical medicine as well as director of Clinical Allergy and Immunology. He remains a part of the UCSF community, serving as an adjunct professor of medicine.

Adelman has also been a member of the editorial boards of Clinical Immunology and the Journal of Clinical Immunology, and served as a clinical advisor to several biopharma firms.